Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia

International Journal of Cardiology

Volumn 199, Issue , 2015, Pages 126-131

  Koh, Kwang Kon ^a,b   Oh, Pyung Chun ^a,b   Sakuma, Ichiro ^b   Kim, Eun Young ^a   Lee, Yonghee ^c   Hayashi, Toshio ^d   Han, Seung Hwan ^a,b   Park, Yae Min ^a,b   Shin, Eak Kyun ^a,b  

^a Gachon University College of Medicine   (South Korea)

^b Gachon Cardiovascular Research Institute ^*  (Japan)

^c University of Seoul   (South Korea)

^d NAGOYA UNIVERSITY   (Japan)

Author keywords

Ezetimibe; Fat; Hypercholesterolemia hypertension; Insulin resistance; Statins

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; EZETIMIBE; HEMOGLOBIN A1C; INSULIN; PLACEBO; SIMVASTATIN; ADIPOQ PROTEIN, HUMAN; ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ABDOMINAL OBESITY; ADULT; ARTICLE; BLOOD FLOW; BLOOD PRESSURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; VASODILATATION; VASOMOTOR REFLEX; AGED; ANIMAL; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECTS; FAT BODY; HYPERTENSION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAT; SINGLE BLIND PROCEDURE;

ADIPONECTIN; AGED; ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; EZETIMIBE; FAT BODY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOLIPIDEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; SIMVASTATIN; SINGLE-BLIND METHOD;

EID: 84941570981     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.07.016     Document Type: Article

References (36)

1. F.M. Sacks, A.M. Tonkin, J. Shepherd, E. Braunwald, S. Cobbe, C.M. Hawkins, A. Keech, C. Packard, J. Simes, R. Byington, and C.D. Furberg Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project Circulation 102 2000 1893 1900
2. J. Kim, K.K. Koh, and M.J. Quon The union of vascular and metabolic actions of insulin in sickness and in health Arterioscler. Thromb. Vasc. Biol. 25 2005 889 891
3. J. Kim, M. Montagnani, K.K. Koh, and M.J. Quon Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms Circulation 113 2006 1888 1904
4. S.H. Han, M.J. Quon, and K.K. Koh Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction Curr. Opin. Lipidol. 18 2007 58 65
5. K.K. Koh Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability Cardiovasc. Res. 47 2000 648 657
6. J.W. Kim, K.H. Yun, E.K. Kim, Y.C. Kim, D.Y. Joe, J.S. Ko, S.J. Rhee, E.M. Lee, N.J. Yoo, N.H. Kim, S.K. Oh, and J.W. Jeong Effect of high dose rosuvastatin loading before primary percutaneous coronary intervention on infarct size in patients with ST-segment elevation myocardial infarction KORn Circ. J. 44 2014 76 81
7. S. Lim, I. Sakuma, M.J. Quon, and K.K. Koh Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality Int. J. Cardiol. 167 2013 1696 1702
8. K.K. Koh, M.J. Quon, S.H. Han, Y. Lee, J.Y. Ahn, S.J. Kim, Y. Koh, and E.K. Shin Simvastatin improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients Diabetes Care 31 2008 776 782
9. K.K. Koh, M.J. Quon, S.H. Han, Y. Lee, S.J. Kim, and E.K. Shin Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients J. Am. Coll. Cardiol. 55 2010 1209 1216
10. M1. Deushi, M. Nomura, A. Kawakami, M. Haraguchi, M. Ito, M. Okazaki, H. Ishii, and M. Yoshida Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome FEBS Lett. 581 2007 5664 5670
11. E.D. Labonté, L.M. Camarota, J.C. Rojas, R.J. Jandacek, D.E. Gilham, J.P. Davies, Y.A. Ioannou, P. Tso, D.Y. Hui, and P.N. Howles Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1 -/- mice Am. J. Physiol. Gastrointest. Liver Physiol. 295 2008 G776 G783
12. D.C. Chan, G.F. Watts, S.K. Gan, E.M. Ooi, and P.H. Barrett Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet Diabetes Care 33 2010 1134 1139
13. H. Takase, Y. Dohi, T. Okado, T. Hashimoto, Y. Goto, and G. Kimura Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study Eur. J. Clin. Investig. 42 2012 1287 1294
14. K.K. Koh, M.J. Quon, S.H. Han, W.-J. Chung, J.Y. Ahn, Y.-H. Seo, M.H. Kang, T.H. Ahn, I.S. Choi, and E.K. Shin Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients Circulation 110 2004 3687 3692
15. K.K. Koh, M.J. Quon, I. Sakuma, Y. Lee, S. Lim, S.H. Han, and E.K. Shin Effects of simvastatin therapy on circulating adipocytokines in patients with hypercholesterolemia Int. J. Cardiol. 146 2011 434 437
16. K.K. Koh, M.J. Quon, I. Sakuma, S.H. Han, H. Choi, K. Lee, and E.K. Shin Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients Int. J. Cardiol. 166 2013 509 515
17. K.K. Koh, S. Lim, H. Choi, Y. Lee, S.H. Han, K. Lee, P.C. Oh, I. Sakuma, E.K. Shin, and M.J. Quon Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia Diabetes 62 2013 3547 3552
18. P.C. Oh, K.K. Koh, I. Sakuma, S. Lim, Y. Lee, S. Lee, K. Lee, S.H. Han, and E.K. Shin Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia Int. J. Cardiol. 176 2014 696 702
19. A. Katz, S.S. Nambi, K. Mather, A.D. Baron, D.A. Follmann, G. Sullivan, and M.J. Quon Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans J. Clin. Endocrinol. Metab. 85 2000 2402 2410
20. R. Muniyappa, S. Lee, H. Chen, and M.J. Quon Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage Am. J. Physiol. Endocrinol. Metab. 294 2008 e15 e26
21. S. Jackson, and R. Thomas Computed tomography (CT): clinical applications of CT S. Jackson, R. Thomas, Cross-Sectional Imaging Made Easy 2004 Churchill Livingstone Oxford (Chapter 2)
22. Examination Committee of Criteria for 'Obesity Disease' in Japan, and Japan Society for the Study of Obesity New criteria for 'obesity disease' in Japan Circ. J. 66 2002 987 992
23. T. Tsunoda, T. Nozue, M. Yamada, I. Mizuguchi, M. Sasaki, and I. Michishita Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance Diabetes Res. Clin. Pract. 100 2013 46 52
24. Y.H. Choi, Y. Kim, C.W. Hyeon, S. Hyun, J.E. Kwon, H. Won, S.Y. Shin, W.S. Lee, K.J. Lee, S.W. Kim, T.H. Kim, and C.J. Kim Influence of previous statin therapy on cholesterol-lowering effect of ezetimibe KORn Circ. J. 44 2014 227 232
25. S.H. Han, M.J. Quon, J.A. Kim, and K.K. Koh Adiponectin and cardiovascular disease: response to therapeutic interventions J. Am. Coll. Cardiol. 49 2007 531 538
26. S. Lim, M.J. Quon, and K.K. Koh Modulation of adiponectin as a potential therapeutic strategy Atherosclerosis 233 2014 721 728
27. T. Pischon, C.J. Girman, G.S. Hotamisligil, N. Rifai, F.B. Hu, and E.B. Rimm Plasma adiponectin levels and risk of myocardial infarction in men JAMA 291 2004 1730 1737
28. S. Li, H.J. Shin, E.L. Ding, and R.M. van Dam Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis JAMA 302 2009 179 188
29. A.J. Hanley, K. Williams, C. Gonzalez, R.B. D'Agostino Jr., L.E. Wagenknecht, M.P. Stern, S.M. Haffner, San Antonio Heart Study, Mexico City Diabetes Study, and Insulin Resistance Atherosclerosis Study Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study Diabetes 52 2003 463 469
30. F.F1. Ribeiro-Filho, A.N. Faria, O. Kohlmann Jr., S. Ajzen, A.B. Ribeiro, M.T. Zanella, and S.R. Ferreira Ultrasonography for the evaluation of visceral fat and cardiovascular risk Hypertension 38 2001 713 717
31. K1. Asayama, K. Dobashi, H. Hayashibe, K. Kodera, N. Uchida, T. Nakane, T. Araki, and S. Nakazawa Threshold values of visceral fat measures and their anthropometric alternatives for metabolic derangement in Japanese obese boys Int. J. Obes. Relat. Metab. Disord. 26 2002 208 213
32. K.K. Koh, M.J. Quon, and M.A. Waclawiw Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis 196 2008 1 8
33. A. Varbo, M. Benn, G.D. Smith, N.J. Timpson, A. Tybjaerg-Hansen, and B.G. Nordestgaard Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease Circ. Res. 116 2015 665 673
34. M1. Satoh, T1. Ohkubo, K1. Asayama, Y1. Murakami, M1. Sakurai, H1. Nakagawa, H1. Iso, A1. Okayama, K1. Miura, Y1. Imai, H1. Ueshima, T1. Okamura, and Evidence for Cardiovascular Prevention From Observational Cohorts in Japan (EPOCH-JAPAN) Research Group∗ Combined effect of blood pressure and total cholesterol levels on long-term risks of subtypes of cardiovascular death: evidence for cardiovascular prevention from observational cohorts in Japan Hypertension 65 2015 517 524
35. D.I. Swerdlow, D. Preiss, K.B. Kuchenbaecker, M.V. Holmes, J.E. Engmann, T. Shah, R. Sofat, S. Stender, P.C. Johnson, R.A. Scott, M. Leusink, N. Verweij, S.J. Sharp, Y. Guo, C. Giambartolomei, C. Chung, A. Peasey, A. Amuzu, K. Li, J. Palmen, P. Howard, J.A. Cooper, F. Drenos, Y.R. Li, G. Lowe, J. Gallacher, M.C. Stewart, I. Tzoulaki, S.G. Buxbaum, A.D.L. van der, N.G. Forouhi, N.C. Onland-Moret, Y.T. van der Schouw, R.B. Schnabel, J.A. Hubacek, R. Kubinova, M. Baceviciene, A. Tamosiunas, A. Pajak, R. Topor-Madry, U. Stepaniak, S. Malyutina, D. Baldassarre, B. Sennblad, E. Tremoli, U. de Faire, F. Veglia, I. Ford, J.W. Jukema, R.G. Westendorp, G.J. de Borst, P.A. de Jong, A. Algra, W. Spiering, A.H. Maitland-van der Zee, O.H. Klungel, A. de Boer, P.A. Doevendans, C.B. Eaton, J.G. Robinson, D. Duggan, DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium, J. Kjekshus, J.R. Downs, A.M. Gotto, A.C. Keech, R. Marchioli, G. Tognoni, P.S. Sever, N.R. Poulter, D.D. Waters, T.R. Pedersen, P. Amarenco, H. Nakamura, J.J. McMurray, J.D. Lewsey, D.I. Chasman, P.M. Ridker, A.P. Maggioni, L. Tavazzi, K.K. Ray, S.R. Seshasai, J.E. Manson, J.F. Price, P.H. Whincup, R.W. Morris, D.A. Lawlor, G.D. Smith, Y. Ben-Shlomo, P.J. Schreiner, M. Fornage, D.S. Siscovick, M. Cushman, M. Kumari, N.J. Wareham, W.M. Verschuren, S. Redline, S.R. Patel, J.C. Whittaker, A. Hamsten, J.A. Delaney, C. Dale, T.R. Gaunt, A. Wong, D. Kuh, R. Hardy, S. Kathiresan, B.A. Castillo, P. van der Harst, E.J. Brunner, A. Tybjaerg-Hansen, M.G. Marmot, R.M. Krauss, M. Tsai, J. Coresh, R.C. Hoogeveen, B.M. Psaty, L.A. Lange, H. Hakonarson, F. Dudbridge, S.E. Humphries, P.J. Talmud, M. Kivimäki, N.J. Timpson, C. Langenberg, F.W. Asselbergs, M. Voevoda, M. Bobak, H. Pikhart, J.G. Wilson, A.P. Reiner, B.J. Keating, A.D. Hingorani, and N. Sattar HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials Lancet 385 2015 351 361
36. J1. Besseling, J.J1. Kastelein, J.C2. Defesche, B.A3. Hutten, and G.K1. Hovingh Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus JAMA 313 2015 1029 1036